Glucocorticoid dosing (mg/day, prednisolone equivalent) with rituximab or cyclophosphamide-based regimens for remission induction in GPA or MPA according to the PEXIVAS Study93
| Weeks | Body weight (kg) | ||
| <50 | 50–75 | >75 | |
| 1* | 50 | 60 | 75 |
| 2 | 25 | 30 | 40 |
| 3–4 | 20 | 25 | 30 |
| 5–6 | 15 | 20 | 25 |
| 7–8 | 12.5 | 15 | 20 |
| 9–10 | 10 | 12.5 | 15 |
| 11–12 | 7.5 | 10 | 12.5 |
| 13–14 | 6 | 7.5 | 10 |
| 15–18 | 5 | 5 | 7.5 |
| 19–52 | 5 | 5 | 5 |
| >52 | Individual taper | Individual taper | Individual taper |
*Consider use of intravenous methylprednisolone at a cumulative dose of 1–3 g on days 1–3 in patients with severely active disease, including but not limited to renal involvement with a documented estimated glomerular filtration rate <50 mL/min/1.73 m2 and/or diffuse alveolar haemorrhage.
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.